M Ventures | Activity

Investment

Led Remepy's $36M Series A to expand its Hybrid Drug pipeline and advance Hybridopa for Parkinson's disease.

Remepy

Remepy M Ventures

m-ventures.comAUG 12, 2026

AUG 12, 2026

Investment

Co-led Cyllene Therapeutics' EUR33 million Series C raise alongside GordonMD.

Cyllene Therapeutics

Cyllene Therapeutics M Ventures

m-ventures.comJUL 7, 2026

JUL 7, 2026

Milestone

LabGenius and LG Chem entered a research collaboration to develop an AI/ML-designed tumor-targeting antibody.

LabGenius

LabGeniusM Ventures

m-ventures.comJUN 19, 2026

JUN 19, 2026

Milestone

Nouscom's NOUS-209 immunotherapy received FDA fast track designation for preventing Lynch syndrome-associated cancers.

Nouscom

Nouscom M Ventures

m-ventures.comJUN 1, 2026

JUN 1, 2026

Milestone

Artios dosed the first patient in its randomized Phase 2 POLKA study of DNA polymerase theta inhibitor ART6043 in breast cancer.

Artios

Artios M Ventures

m-ventures.comMAY 26, 2026

MAY 26, 2026

Milestone

Storm Therapeutics presented Phase 1 sarcoma data for its first-in-class METTL3 inhibitor STC-15 at ASCO 2026.

Storm Therapeutics

Storm Therapeutics M Ventures

m-ventures.comMAY 23, 2026

MAY 23, 2026

Milestone

Boehringer Ingelheim licensed a preclinical antibody program from Immunitas to advance treatments for chronic inflammatory disease.

Immunitas

Immunitas M Ventures

m-ventures.comMAY 12, 2026

MAY 12, 2026

Milestone

Theolytics dosed the first patient in its US Phase 1 OCTOPOD-IP trial of oncolytic immunotherapy THEO-260.

Theolytics

Theolytics M Ventures

m-ventures.comAPR 28, 2026

APR 28, 2026

Investment

Storm Therapeutics secured $56M in Series C financing and dosed its first Phase 2 patient with STC-15.

Storm Therapeutics

Storm Therapeutics M Ventures

m-ventures.comAPR 17, 2026

APR 17, 2026

Investment

Lightcast raised $27M and added an industry veteran to accelerate commercialization of its Envisia platform.

Lightcast

Lightcast M Ventures

m-ventures.comAPR 15, 2026

APR 15, 2026

Milestone

Repronovo appointed Mark Altmeyer as Chairman of the Board.

ReproNovo

ReproNovo M Ventures

m-ventures.comMAR 20, 2026

MAR 20, 2026

Milestone

Outrun Therapeutics unveiled its lead program targeting HPV-positive head and neck cancer and appointed E3 ligase experts to its advisory board.

Outrun Therapeutics

Outrun Therapeutics M Ventures

m-ventures.comMAR 18, 2026

MAR 18, 2026

Milestone

Enara Bio presented its first-in-class DARKFOX-targeting bispecific T cell engager ENA101 at AACR 2026.

Enara Bio

Enara Bio M Ventures

m-ventures.comMAR 18, 2026

MAR 18, 2026

M Ventures Activity

Led Remepy's $36M Series A to expand its Hybrid Drug pipeline and advance Hybridopa for Parkinson's disease.

Cyllene Therapeutics expanded its leadership team, appointing a new board member and two VPs, to support corporate growth.

Co-led Cyllene Therapeutics' EUR33 million Series C raise alongside GordonMD.

LabGenius and LG Chem entered a research collaboration to develop an AI/ML-designed tumor-targeting antibody.

Nouscom's NOUS-209 immunotherapy received FDA fast track designation for preventing Lynch syndrome-associated cancers.

Artios dosed the first patient in its randomized Phase 2 POLKA study of DNA polymerase theta inhibitor ART6043 in breast cancer.

Storm Therapeutics presented Phase 1 sarcoma data for its first-in-class METTL3 inhibitor STC-15 at ASCO 2026.

Boehringer Ingelheim licensed a preclinical antibody program from Immunitas to advance treatments for chronic inflammatory disease.

Theolytics dosed the first patient in its US Phase 1 OCTOPOD-IP trial of oncolytic immunotherapy THEO-260.

Storm Therapeutics secured $56M in Series C financing and dosed its first Phase 2 patient with STC-15.

Lightcast raised $27M and added an industry veteran to accelerate commercialization of its Envisia platform.

Repronovo appointed Mark Altmeyer as Chairman of the Board.

Outrun Therapeutics unveiled its lead program targeting HPV-positive head and neck cancer and appointed E3 ligase experts to its advisory board.

Enara Bio presented its first-in-class DARKFOX-targeting bispecific T cell engager ENA101 at AACR 2026.